FDA Authorizes changes to COVID-19 Vaccines – Yet Switzerland stopped them?

FDA supports simplifying mRNA bivalent COVID-19 vaccines to encourage future vaccination. • 0:39

FDA emphasizes the benefits of vaccination outweigh potential risks, urging individuals to stay current with vaccines. • 2:10

FDA’s decision based on evidence of antibodies in most of the U.S. population aged five and older, supporting continued vaccination. • 2:26

Switzerland found 97% of the population already had antibodies from vaccination or infection as a basis for their decision. • 2:51

Switzerland recommends no COVID-19 vaccination for spring or summer 2023, except for high-risk individuals. • 3:55

Switzerland does not recommend COVID-19 vaccination for high-risk individuals, unlike the United States. • 4:19

In Switzerland, vaccination decisions are made after individual consultations with doctors, while in the United States, it is individual responsibility. • 5:08

Switzerland does not recommend the bivalent vaccine, which includes the Omicron variant, while the United States encourages its use. • 5:31

The importance of natural immunity in preventing severe disease is emphasized, highlighting the differences between natural and vaccine-induced immunity. • 6:05

Mucosal immunity plays a crucial role in blocking infections at the upper Airways barrier, complemented by systemic immunity from lymph nodes. • 7:07

IGG antibodies primarily created in lymph nodes, impacting systemic immunity more than mucosal immunity. • 8:04

Injectable vaccines show reduction in severe disease but may not fully support mucosal immunity. • 8:40

China explored mucosal vaccines with potential success in overcoming the pandemic. • 9:22

Importance of understanding evolving science in COVID-19 response and the need for transparency. • 10:03

Continued focus on updating and explaining scientific developments in the pandemic response. • 10:31